Please use this identifier to cite or link to this item:http://hdl.handle.net/20.500.12105/10375
Design of the β3-Adrenergic Agonist Treatment in Chronic Pulmonary Hypertension Secondary to Heart Failure Trial.
Garcia-Lunar, Ines CNIC | Blanco, Isabel | Fernandez-Friera, Leticia CNIC | Prat-Gonzàlez, Susanna | Jordà, Paloma | Sánchez, Javier | Pereda, Daniel CNIC | Pujadas, Sandra | Rivas, Mercedes | Solé-Gonzalez, Eduard | Vázquez, Jorge | Blázquez, Zorba | García-Picart, Juan | Caravaca, Pedro | Escalera, Noemí | Garcia-Pavia, Pablo CNIC | Delgado, Juan | Segovia-Cubero, Javier | Fuster, Valentin CNIC | Roig, Eulalia | Barberá, Joan Albert | Ibanez, Borja CNIC | Garcia-Alvarez, Ana CNIC
JACC Basic Transl Sci. 2020; 5(4):317-327
Combined pre-and post-capillary hypertension (CpcPH) is a relatively common complication of heart failure (HF) associated with a poor prognosis. Currently, there is no specific therapy approved for this entity. Recently, treatment with beta-3 adrenergic receptor (β3AR) agonists was able to improve pulmonary hemodynamics and right ventricular (RV) performance in a translational, large animal model of chronic PH. The authors present the design of a phase II randomized clinical trial that tests the benefits of mirabegron (a clinically available β3AR agonist) in patients with CpcPH due to HF. The effect of β3AR treatment will be evaluated on pulmonary hemodynamics, as well as clinical, biochemical, and advanced cardiac imaging parameters. (Beta3 Agonist Treatment in Chronic Pulmonary Hypertension Secondary to Heart Failure [SPHERE-HF]; NCT02775539).
Files in this item
- DesignBeta3-AdrenergicAgonist_ ...